Venmax Drugs approves FY26 AGM notice, director appointments
- Board approved FY26 annual report and 37th AGM notice
- Venkata Rao Sadhanala appointed Managing Director with ₹30 lakh annual pay
- Two additional directors regularized with no managerial remuneration
- AGM scheduled for September 26, 2026 via video conferencing
*this image is generated using AI for illustrative purposes only.
Venmax Drugs & Pharmaceuticals approved its 37th Annual General Meeting (AGM) notice and key director appointments during a board meeting on August 31, 2026. The company will hold the AGM via video conferencing on September 26, 2026.
The board approved the Notice, Directors Report, and Annual Report for FY26. It also cleared the Secretarial Audit Report issued by M/S Kashinath Sahu & Co.
Director Appointments
The board recommended three key governance changes for shareholder approval at the AGM:
- Venkata Rao Sadhanala: Designation changed from Whole-Time Director to Managing Director for five years, effective March 11, 2026. His remuneration is set at ₹30 lakh per annum including perquisites.
- Padmaja Kalyani Sadhanala: Regularized as Non-Executive Non-Independent Director from March 30, 2026. She receives no managerial remuneration.
- Revoor Ramachandra: Regularized as Non-Executive Independent Director for a five-year term from March 30, 2026. He also receives no managerial remuneration.
AGM Logistics
Shareholders can vote electronically via the CDSL E-Voting Platform. Remote e-voting runs from September 23 to September 25, 2026. The cut-off date for voting eligibility is September 18, 2026.
| Particulars | Details |
|---|---|
| E-Voting Start Date | September 23, 2026 - 9:00 am |
| E-Voting End Date | September 25, 2026 - 5:00 pm |
| Cut-off Date | September 18, 2026 |
The Register of Members and Share Transfer Books remain closed from September 18 to September 26, 2026. M/s Kashinath Sahu & Co. has been appointed as the scrutinizer for the e-voting process.
Historical Stock Returns for Venmax Drugs & Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.88% | -1.49% | -9.79% | -37.61% | -52.80% | 0.0% |
How might Venkata Rao Sadhanala's transition from Whole-Time Director to Managing Director influence Venmax Drugs & Pharmaceuticals' strategic direction and business expansion plans?
What impact could the new board composition, including the addition of an independent director, have on Venmax's corporate governance ratings and investor confidence?
Given the ₹30 lakh annual remuneration package for the Managing Director, how does this compare to industry peers and could it attract or retain top pharmaceutical talent?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
